Equity Incentive Plans (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 20, 2017	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jul. 02, 2024	Jun. 16, 2023	Jun. 16, 2022
Options
Outstanding balance at the beginning of the period (in shares)				3,384,366
Granted (in shares)				1,727,500
Exercised (in shares)				(10,557)
Forfeited (in shares)				(254,674)
Outstanding balance at the end of the period (in shares)		4,846,635		4,846,635		3,384,366
Options exercisable at the end of the period (in shares)		2,396,563		2,396,563
Options vested and expected to vest at end of period (in shares)		4,846,635		4,846,635
Weighted Average Exercise Price Per Share
Outstanding balance at the beginning of the period (in dollars per share)				$ 13.97
Granted (in dollars per share)				2.67
Exercised (in dollars per share)				2.77
Forfeited (in dollars per share)				5.69
Outstanding balance at the end of the period (in dollars per share)		$ 10.40		10.40		$ 13.97
Options exercisable at the end of the period (in dollars per share)		17.90		17.90
Options vested and expected to vest at end of the period (in dollars per share)		$ 10.40		$ 10.40
Weighted Average Remaining Life in Years
Outstanding balance				8 years 2 months 26 days		8 years 4 months 24 days
Options exercisable at end of period				7 years 4 months 24 days
Options vested and expected to vest at end of the period				8 years 2 months 26 days
Aggregate Intrinsic Value
Outstanding balance		$ 527		$ 527		$ 3,431
Options vested and expected to vest at end of the period		527		$ 527
Assumptions used to determine grant-date fair value
Expected volatility				92.99%	90.37%
Weighted average risk-free interest rate				3.98%	4.05%
Expected dividend yield				0.00%	0.00%
Expected term (in years)				6 years 5 months 15 days	6 years 5 months 23 days
Expiration period				10 years
Unrecognized compensation cost related to non-vested stock options		5,633		$ 5,633
Weighted average period for recognition of compensation cost				1 year 11 months 4 days
Minimum
Assumptions used to determine grant-date fair value
Vesting period				3 years
Maximum
Assumptions used to determine grant-date fair value
Vesting period				4 years
Options to purchase common stock
Weighted Average Exercise Price Per Share
Granted (in dollars per share)				$ 2.12	$ 2.09
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense		1,339	$ 1,300	$ 3,957	$ 3,875
Options to purchase common stock | Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense		720	737	2,076	2,086
Options to purchase common stock | General and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Stock Based Compensation Expense		619	$ 563	$ 1,881	$ 1,789
Restricted stock units to purchase common stock
Assumptions used to determine grant-date fair value
Weighted average period for recognition of compensation cost				4 months 17 days
Vested				$ 4,388
Unrecognized compensation costs related to RSUs granted to employees		$ 516		$ 516
2016 Plan
Assumptions used to determine grant-date fair value
Annual increase in authorized shares (as a percent)	4.00%
2016 Plan | Restricted stock units to purchase common stock
Assumptions used to determine grant-date fair value
Options unvested at end of period (in dollars per share)		$ 19.29		$ 19.29		$ 19.97
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding at the beginning				262,500
Vested (in shares)				(27,500)
Forfeited (in shares)				(7,500)
Outstanding at the end		227,500		227,500		262,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Non vested, Weighted Average Grant Date Fair Value
Outstanding at beginning( in dollars per share)				$ 19.97
Vested(in dollars per share)				25.70
Forfeited (in dollars per share)				19.40
Outstanding at end(in dollars per share)		$ 19.29		$ 19.29		$ 19.97
2022 Plan
Assumptions used to determine grant-date fair value
Common shares reserved for issuance							2,000,000	2,250,000
Number of options or stock awards available for grant under the Plan									750,000
2016 and 2022 Plan
Assumptions used to determine grant-date fair value
Number of options or stock awards available for grant under the Plan		2,573,313		2,573,313